ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd announced receiving clinical trial approval from the US FDA for its IMM2520, a bispecific antibody (BsAb) targeting CD47 and PD-L1 in solid tumors.
Mechanism of Action and Preclinical Results
IMM2520, featuring functional IgG1 Fc, can activate macrophages and T cells simultaneously by targeting CD47 and PD-L1 in tumor cells to achieve strong synergy and induce lasting tumor-specific immune responses. The drug has demonstrated encouraging in vivo efficacy and safety in a variety of animal models.
Patent and Regulatory Status
Previously, IMM2520, under patent protection in Japan, is under patent filing review in China, the United States, the European Union, and other regions. The drug obtained clinical trial approval in China last month.-Fineline Info & Tech
